Entries Tagged as 'Statistics'

Monday, February 10th, 2014

Q4 2013 Drug Sales Data Released: Tecfidera Growth On a Rapid Transit

Drugs.com has released the latest U.S. drug sales data. While the ranking of the top three drugs by sales — Abilify, Nexium and Humira — remains the same, Lilly’s Cymbalta drops from fourth to seventh and forfeits close to $319 million in sales due to generic availability. Nexium’s growth tapers too, possibly due to looming […]

Thursday, November 7th, 2013

Q3 2013 Drug Sales Data Released: Top Five Drugs Each Post Over $1 Billion in Sales

The latest U.S. drug sales data has been released by Drugs.com. Rankings for the top five drugs by sales remain unchanged in the third quarter. Otsuka’s antipsychotic Abilify and AstraZeneca’s Nexium retain their number one and two spots, respectively. Nexium, the top proton pump inhibitor faces sizable over-the-counter competition, a looming Rx-to-OTC switch, and patent […]

Thursday, August 8th, 2013

Q2 2013 Drug Sales Data Released: Humira Climbs and Posts Double-Digit Growth

The latest U.S. drug sales data has been released by Drugs.com. Since Q2 2012, Otuska’s antipsychotic Abilify and AstraZeneca’s acid reducer Nexium have held either the number one or two spot in top dollar sales. This quarter, both agents continue to maintain their stronghold; each post close to $1.5 billion in sales. Humira, AbbVie’s key […]

Sunday, May 5th, 2013

Q1 2013 Drug Sales Data Released: Rough U.S Flu Season Boosts Numbers for Tamiflu

The latest U.S. drug sales data has been released by Drugs.com. The top five drugs have minor shifts in rank but exhibit positive growth for Q1 2013. Abilify, Otsuka’s second generation antipsychotic, and Nexium, AstraZeneca’s leading acid blocker, rank as the top two drugs by sales for the fourth quarter in a row. Both agents […]

Thursday, February 7th, 2013

Q4 2012 Drug Sales Data Released: Abilify Overtakes Nexium as the Top Drug by Sales

The latest U.S. drug sales data have been released by Drugs.com. At the close of 2012, Otsuka’s antipsychotic Abilify overtakes AstraZeneca’s acid reducer Nexium and moves into the number one spot with over $1.47 billion in quarterly sales. Sales expanded for all five front-runners over the quarter, although none reached double-digit growth. There are no […]

Wednesday, November 21st, 2012

Q3 2012 Drug Sales Data Released: Nexium and Abilify Remain the Leading Brands

The latest U.S. drug sales data has been released by Drugs.com. As in the previous quarter, proton-pump inhibitors, antipsychotics and statins remain in the top-selling therapeutic categories. Merck’s asthma and allergy preventive Singulair predictably drops out of the top five drugs due to Q3 patent loss. AstraZeneca’s Nexium, not forecast to lose patent protection until May 2014, […]

Wednesday, August 22nd, 2012

Q2 2012 Drug Sales Data Released: Loss of Patent Protection Has Significant Effect

The latest U.S. drug sales data has been released by Drugs.com. Proton-pump inhibitors, antipsychotics, asthma therapeutics and statins remain the top selling categories. Plavix and Seroquel dipped in the second quarter due to loss of patent protection. Other top brands such as Singulair, Actos and Diovan are also due to be impacted by year’s end. […]

Wednesday, July 18th, 2012

New Drugs.com Stats Center Shows Top 100 U.S. Drug Sales Data

We are pleased to announce our new interactive stats center featuring quarterly sales data for the top 100 prescribed medicines by U.S. National Sales. Users can view charts showing the sales and unit data for the top 5 drugs plus granular data for the top 100, with graphs and links to other useful resources. This […]

Monday, June 29th, 2009

A Side Effect of Michael Jackson’s Tragic Death – Consumer Health Education

Drugs.com reported a massive 20,900% increase (yes, you read that correctly – twenty thousand, nine hundred percent) in interest for information on the prescription medication Demerol – allegedly prescribed for the legendary entertainer Michael Jackson. More than 135,000 page views were logged on the Drugs.com web site by people researching Demerol this past Friday – […]